Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 7,007 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urologic Diseases Clear all
Completed Phase 2 Interventional

Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol

NCT00390624
View directory record Official record
Conditions
Renal Dysfunction, Acute Renal Failure, Mortality
Interventions
URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE), MANNITOL
Drug
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 3, 2008 · Synced Oct 16, 2026, 3:14 AM EDT
Withdrawn Phase 2 Interventional

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

NCT01355562
View directory record Official record
Conditions
Melanoma, Metastatic Kidney Cancer
Interventions
Interleukin-2 (IL-2)
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Beaumont, California • Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 16, 2026, 3:14 AM EDT
Terminated Not applicable Interventional Results available

Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients

NCT02165761
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
GORE® Hybrid Vascular Graft, Non-heparin bonded synthetic graft
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Hackensack, New Jersey • Charlotte, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 16, 2026, 3:14 AM EDT
Withdrawn No phase listed Observational

Study to Determine the Impact of Intraoperative Blood Pressure Management on Postoperative Outcomes (MAP-ALIVE)

NCT02019342
View directory record Official record
Conditions
Death, Postoperative Complications, Myocardial Infarction, Stroke, Renal Failure
Interventions
FACE quality improvement initiative (see below), Pre-quality improvement initiative
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Ann Arbor, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 16, 2026, 3:14 AM EDT
Completed Not applicable Interventional Results available

Home-Based Exercise to Treat Decreased Physical Function in Patients With Varying Levels of Kidney Function

NCT04745169
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
8 week home-based exercise program
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 16, 2026, 3:14 AM EDT
Terminated Phase 3 Interventional Results available

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

NCT00616902
View directory record Official record
Conditions
Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular
Interventions
paricalcitol injection 4 mcg/mL, Placebo Injection 4 mcg/mL
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
29
States / cities
Phoenix, Arizona • Tempe, Arizona • Bakersfield, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 16, 2026, 3:14 AM EDT
Completed Phase 1 Interventional

The Role of Endothelin-1 in Sickle Cell Disease

NCT02712346
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Ambrisentan, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 16, 2026, 3:14 AM EDT
Recruiting No phase listed Observational

A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer

NCT03193541
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
900 participants
Timeline
2016 – 2029
U.S. locations
6
States / cities
Long Beach, California • Los Angeles, California • Newport Beach, California + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 16, 2026, 3:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

NCT01571596
View directory record Official record
Conditions
X-linked Hypophosphatemia
Interventions
KRN23
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 16, 2026, 3:14 AM EDT
Recruiting Not applicable Interventional

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

NCT07195656
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Device Group, Medication Group
Device · Drug
Lead sponsor
FemPulse Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Beverly Hills, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 16, 2026, 3:14 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

NCT05137262
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Abiraterone acetate, Durvalumab, Methotrexate, Vinblastine, Doxorubicin Hydrochloride, Cisplatin
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Bloomington, Indiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 16, 2026, 3:14 AM EDT
Not listed No phase listed Observational

Malnutrition, Diet and Racial Disparities in Chronic Kidney Disease (CKD)

NCT01415570
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), End-Stage Renal Disease (ESRD)
Interventions
Not listed
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 16, 2026, 3:14 AM EDT
Not yet recruiting Phase 4 Interventional

Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease

NCT07187466
View directory record Official record
Conditions
Overactive Bladder, Parkinson Disease
Interventions
mirabegron, Exercise-based behavioral therapy
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Decatur, Georgia • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 16, 2026, 3:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

SPL Insufficiency Syndrome (SPLIS)/NPHS14: a SPLIS Observational Study and Patient Registry (International)

NCT04885179
View directory record Official record
Conditions
Sphingolipidoses, Enzyme Deficiency
Interventions
no intervention
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 16, 2026, 3:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer

NCT04386746
View directory record Official record
Conditions
Urothelial Carcinoma Bladder, Bladder Cancer
Interventions
Gemcitabine, Docetaxel
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 16, 2026, 3:14 AM EDT
Terminated Phase 3 Interventional

Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment

NCT00958269
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Renal Impairment
Interventions
dutogliptin, placebo, sitagliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Tempe, Arizona • Long Beach, California • Lynwood, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 16, 2026, 3:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Oral Probiotics to Reduce Urinary Oxalate Excretion

NCT00587041
View directory record Official record
Conditions
Nephrolithiasis, Hyperoxaluria, Crohn's Disease
Interventions
Oxadrop, Agri-King Synbiotic (AKSB), Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 16, 2026, 3:14 AM EDT
Completed Not applicable Interventional Results available

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

NCT00428220
View directory record Official record
Conditions
Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer, Non-Small Cell Lung Cancer, Thyroid Cancer, Advanced/Metastatic Non-Small Cell Lung Cancer, Advanced Gastric Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma, Pancreatic Islet Cell Carcinoma, Pancreatic Neuroendocrine Tumor
Interventions
sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Atlanta, Georgia • Maywood, Illinois • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 16, 2026, 3:14 AM EDT
Completed Phase 1 Interventional

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00082823
View directory record Official record
Conditions
Cancer
Interventions
ziv-aflibercept
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 16, 2026, 3:14 AM EDT
Completed Phase 1Phase 2 Interventional

Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

NCT00056173
View directory record Official record
Conditions
Carcinoma, Renal Cell, Metastases, Neoplasm
Interventions
GTI-2040
Drug
Lead sponsor
Aptose Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
10
States / cities
Concord, California • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2008 · Synced Oct 16, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

NCT01589094
View directory record Official record
Conditions
Bladder Cancer
Interventions
Gemcitabine and Cisplatin (DD GC)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 16, 2026, 3:14 AM EDT
Terminated Phase 1 Interventional Results available

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

NCT04628780
View directory record Official record
Conditions
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07209960
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 16, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

NCT01788046
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
45
States / cities
Mobile, Alabama • Azusa, California • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 16, 2026, 3:14 AM EDT
Terminated Phase 3 Interventional Results available

Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer

NCT01987596
View directory record Official record
Conditions
Childhood Choroid Plexus Tumor, Childhood Medulloblastoma, Childhood Pineoblastoma, Childhood Soft Tissue Sarcoma, Childhood Supratentorial Primitive Neuroectodermal Tumor, Neuroblastoma, Osteosarcoma, Retinoblastoma, Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim
Biological
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
1 Year to 25 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 16, 2026, 3:14 AM EDT